129 related articles for article (PubMed ID: 32945439)
1. miR‑592 acts as an oncogene and promotes medullary thyroid cancer tumorigenesis by targeting cyclin‑dependent kinase 8.
Liu T; Meng J; Zhang Y
Mol Med Rep; 2020 Oct; 22(4):3316-3326. PubMed ID: 32945439
[TBL] [Abstract][Full Text] [Related]
2. Two GEO MicroRNA Expression Profile Based High-Throughput Screen to Identify MicroRNA-31-3p Regulating Growth of Medullary Thyroid Carcinoma Cell by Targeting RASA2.
Jiang M; Shi X; Zhu H; Wei W; Li J
Med Sci Monit; 2019 Jul; 25():5170-5180. PubMed ID: 31298226
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-592 suppresses the malignant phenotypes of thyroid cancer by regulating lncRNA NEAT1 and downregulating NOVA1.
Luo Y; Hao T; Zhang J; Zhang M; Sun P; Wu L
Int J Mol Med; 2019 Sep; 44(3):1172-1182. PubMed ID: 31524231
[TBL] [Abstract][Full Text] [Related]
4. Identification and interaction analysis of key miRNAs in medullary thyroid carcinoma by bioinformatics analysis.
Zhang L; Lu D; Liu M; Zhang M; Peng Q
Mol Med Rep; 2019 Sep; 20(3):2316-2324. PubMed ID: 31322209
[TBL] [Abstract][Full Text] [Related]
5. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM
Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of miRNAs expression in medullary thyroid carcinoma tissue samples: miR-34a and miR-144 as promising overexpressed markers in MTC.
Shabani N; Razaviyan J; Paryan M; Tavangar SM; Azizi F; Mohammadi-Yeganeh S; Hedayati M
Hum Pathol; 2018 Sep; 79():212-221. PubMed ID: 29885402
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib.
Lassalle S; Zangari J; Popa A; Ilie M; Hofman V; Long E; Patey M; Tissier F; Belléannée G; Trouette H; Catargi B; Peyrottes I; Sadoul JL; Bordone O; Bonnetaud C; Butori C; Bozec A; Guevara N; Santini J; Hénaoui IS; Lemaire G; Blanck O; Vielh P; Barbry P; Mari B; Brest P; Hofman P
Oncotarget; 2016 May; 7(21):30461-78. PubMed ID: 27036030
[TBL] [Abstract][Full Text] [Related]
8. Identification of microRNAs associated with medullary thyroid carcinoma by bioinformatics analyses.
Fu X; Fang J; Lian M; Zhong Q; Ma H; Feng L; Wang R; Wang H
Mol Med Rep; 2017 Jun; 15(6):4266-4272. PubMed ID: 28487941
[TBL] [Abstract][Full Text] [Related]
9. Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients.
Romeo P; Colombo C; Granata R; Calareso G; Gualeni AV; Dugo M; De Cecco L; Rizzetti MG; Zanframundo A; Aiello A; Carcangiu ML; Gloghini A; Ferrero S; Licitra L; Greco A; Fugazzola L; Locati LD; Borrello MG
Endocr Relat Cancer; 2018 Mar; 25(3):217-231. PubMed ID: 29298817
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA‑592 promotes cell proliferation, migration and invasion in colorectal cancer by directly targeting SPARC.
Pan Z; Xie R; Song W; Gao C
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576452
[TBL] [Abstract][Full Text] [Related]
11. Upregulated miR-9-3p Promotes Cell Growth and Inhibits Apoptosis in Medullary Thyroid Carcinoma by Targeting BLCAP.
Chen Y; Zhang S; Zhao R; Zhao Q; Zhang T
Oncol Res; 2017 Sep; 25(8):1215-1222. PubMed ID: 27938505
[TBL] [Abstract][Full Text] [Related]
12. Assessment of
Pishkari S; Hadavi R; Koochaki A; Razaviyan J; Paryan M; Hashemi M; Mohammadi-Yeganeh S
Horm Mol Biol Clin Investig; 2021 Mar; 42(3):265-271. PubMed ID: 33769725
[TBL] [Abstract][Full Text] [Related]
13. LINC00887 Acts as an Enhancer RNA to Promote Medullary Thyroid Carcinoma Progression by Binding with FOXQ1.
Liu D; Wang W; Wu Y; Qiu Y; Zhang L
Curr Cancer Drug Targets; 2024; 24(5):519-533. PubMed ID: 38804344
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic in medullary thyroid cancer: the role of microRNA in tumorigenesis and prognosis.
Manso J; Censi S; Mian C
Curr Opin Oncol; 2021 Jan; 33(1):9-15. PubMed ID: 33093335
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of miR‑138‑5p promotes non‑small cell lung cancer progression by regulating CDK8.
Xing S; Xu Q; Fan X; Wu S; Tian F
Mol Med Rep; 2019 Dec; 20(6):5272-5278. PubMed ID: 31638208
[TBL] [Abstract][Full Text] [Related]
16. MicroRNAs in Medullary Thyroid Carcinoma: A State of the Art Review of the Regulatory Mechanisms and Future Perspectives.
Galuppini F; Censi S; Moro M; Carraro S; Sbaraglia M; Iacobone M; Fassan M; Mian C; Pennelli G
Cells; 2021 Apr; 10(4):. PubMed ID: 33924120
[TBL] [Abstract][Full Text] [Related]
17. Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.
Chu YH; Lloyd RV
Endocr Pathol; 2016 Dec; 27(4):312-324. PubMed ID: 27539727
[TBL] [Abstract][Full Text] [Related]
18. MiR-375: A prospective regulator in medullary thyroid cancer based on microarray data and bioinformatics analyses.
Shi L; Zhao SM; Luo Y; Zhang AW; Wei LH; Xie ZY; Li YY; Ma W
Pathol Res Pract; 2017 Nov; 213(11):1344-1354. PubMed ID: 29033189
[TBL] [Abstract][Full Text] [Related]
19. Analytical and clinical validation of pairwise microRNA expression analysis to identify medullary thyroid cancer in thyroid fine-needle aspiration samples.
Ciarletto AM; Narick C; Malchoff CD; Massoll NA; Labourier E; Haugh K; Mireskandari A; Finkelstein SD; Kumar G
Cancer Cytopathol; 2021 Mar; 129(3):239-249. PubMed ID: 33017868
[TBL] [Abstract][Full Text] [Related]
20. Integrated analysis of transcription factor-mRNA-miRNA regulatory network related to immune characteristics in medullary thyroid carcinoma.
Weng D; He L; Chen X; Lin H; Ji D; Lu S; Ao L; Wang S
Front Immunol; 2022; 13():1055412. PubMed ID: 36713370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
